India Pharma Outlook Team | Wednesday, 08 June 2022
German drugmaker Boehringer Ingelheim has obtained ad-interim injunctions against four domestic pharmaceutical companies that launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name Trajenta. The recent injunctions restrain the domestic pharma companies
from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing and exporting in any form in India, either by themselves or through their directors, partners, licensees, stockists, distributors, agents etc, jointly and severally until the next date of hearing. Boehringer Ingelheim holds a valid patent for Linagliptin in India until August 2023, the company said in a statement. Commenting on it Vani Manja, MDI, Boehringer Ingelheim India, said, "The swift and just actions of the Hon’ble High Court over the past nine months have reaffirmed our faith in the Indian legal system in securing the enforcement of patent rights and upholding patient interests. This also underlines the strength of Boehringer Ingelheim’s patents.
We continue to remain committed to making a positive difference in the lives of patients with our innovator drugs and expect all responsible corporate citizens to uphold Boehringer Ingelheim’s valid patents for innovator drugs. We believe that upholding patent rights encourages a culture of innovation and R&D in the country. "
, CDSCO.jpg)
